Literature DB >> 3979429

Agonist and antagonist effects of 3-PPP enantiomers on functional dopamine autoreceptors and postsynaptic dopamine receptors in vitro.

A H Mulder, R Draper, P Sminia, A N Schoffelmeer, J C Stoof.   

Abstract

In contrast to racemic 3-PPP (3-(3-hydroxyphenyl)-N-n-propylpiperidine), (+)-3-PPP appeared to inhibit the electrically evoked release of both [3H]dopamine (DA) and [14C]acetylcholine (ACh) from superfused rat neostriatal slices, although it was considerably less potent in this respect that the DA receptor agonists apomorphine, TL-99 (6,7-dihydroxy-N,N-dimethyl-2-aminotetralin) and LY 141865. At concentrations higher than 1 microM both of the 3-PPP enantiomers increased the spontaneous efflux of 3H but not that of 14C. (+)3-PPP also inhibited the cholera toxin-stimulated release of immunoreactive alpha-MSH from dispersed intermediate lobe cells of the rat pituitary gland. The inhibitory effects of (+)3-PPP on both transmitter and alpha-MSH release were antagonized by the selective D-2 receptor antagonist (-)-sulpiride. Neither [3H]DA nor [14C]ACh release were inhibited by (-)3-PPP but, in contrast, the release-inhibiting effect of the selective D-2 receptor agonist LY 141865 as well as that of (+)3-PPP were antagonized by (-)3-PPP, although less effectively than by (-)sulpiride. The inhibitory effect of LY 141865 on alpha-MSH release from intermediate lobe cells was also antagonized by (-)3-PPP. The data indicate that (+)3-PPP is a weak agonist and (-)3-PPP a weak antagonist at D-2 receptors and that neither of the 3-PPP enantiomers interacts selectively with DA autoreceptors mediating presynaptic modulation of striatal DA release.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3979429     DOI: 10.1016/0014-2999(85)90253-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

Review 1.  Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence.

Authors:  D Clark; S Hjorth; A Carlsson
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

2.  Differential effects of 3-PPP enantiomers on extracellular dopamine concentration in the caudate-putamen and nucleus accumbens of rats.

Authors:  R E See
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-12       Impact factor: 3.000

3.  BMY-14802 reverses the reduction of striatal dopamine release induced by (+)-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine.

Authors:  A Kanzaki; K Okumura; H Ujike; K Tsuchida; K Akiyama; S Otsuki
Journal:  J Neural Transm Gen Sect       Date:  1992

4.  Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date.

Authors:  Ferdinando Squitieri; Justo Garcia de Yebenes
Journal:  Drug Des Devel Ther       Date:  2015-10-28       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.